The assay will be used to identify eligible patients for the pivotal trial of a selective FGFR inhibitor that is being evaluated for the treatment of patients with non-central nervous system solid tumors that have a specific gene fusion.
Read More
Use of the combination therapy requires detection of the patient’s status by an FDA-approved test, following progression on or after an endocrine-based regimen.
Read More
Laboratory monitoring supports compliance with medically assisted opioid addiction treatment using buprenorphine
Read More
The study demonstrates the potential for more impactful, dynamic therapy development and applications for those with acute myeloid leukemia.
Read More
Proceeds from the financing will advance the company’s companion diagnostic program, which spans solid tumors, hematological malignancies, and circulating tumor DNA applications.
Read More